Moderna allocates 75% of bird flu vaccine trial recruitment to UK

The launch of the Phase 3 mRNA bird flu vaccine trial highlights the UK’s capacity for rapid, system-wide clinical research delivery. Sponsored by Moderna and supported by the NIHR, the study achieved a major milestone by recruiting its first participant in less than half the government’s 150-day set-up target.

By utilising the NIHR’s Agile Research Delivery Team and the Be Part of Research registry, the trial is being delivered across 26 community sites to ensure inclusive recruitment and high-quality impact.